- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT04053504
Feasibility Study of Family Teamwork Peer-Delivery (TEAM)
The purpose of this study is to 1) convene African American and Latino Community Coalitions to adapt Family Teamwork (FT) for school-age youth, and integrate FT with the Smart and Secure Children (SSC) program community-based, peer delivery format, 2) identify facilitators and barriers to parental involvement in diabetes management for African American and Latino parents of children (5-9 years) with T1D to refine, with Community Coalitions the adapted and integrated Family Teamwork- Peer Delivery (FT-P), and 3) evaluate the feasibility, satisfaction, and preliminary outcomes of the FT-P program among African American and Latino parents of school-aged children (5-9 years) withT1D.
A randomized pilot trials will be conducted with African American and Latino families to examine the feasibility, parent satisfaction, and preliminary outcomes of FT-P. Families will be stratified by race/ethnicity, age, and HbA1c strata, and randomized to FT-P plus standard diabetes care or to standard diabetes care alone after completion of baseline assessment using a random numbers table generated by a program created through Baylor College of Medicine's Institute for Clinical Training and Research data management specialists.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Studietype
Inschrijving (Werkelijk)
Fase
- Niet toepasbaar
Contacten en locaties
Studie Locaties
-
-
Texas
-
Houston, Texas, Verenigde Staten, 77030
- Texas Children's Hospital
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Primary caregiver of a child ages 5-10 years with type 1 diabetes as defined by the American Diabetes Association criteria
- Having a child with diabetes duration of >1 year
- Self-identified African American or Latino race/ethnicity
- Fluent in English
- Not planning to leave the geographic area during the study
Exclusion Criterion:
• Not fluent in English
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
---|---|
Experimenteel: Intervention
Behavioral intervention delivered by parent peer leaders.
|
Children with T1D and their parent will participate in 6 in-person FT-P group sessions during a 12-month period.
Parents will also participate in monthly telephone support calls with a Parent Leader during the 12-month intervention period.
|
Geen tussenkomst: Standard Care
Standard diabetes care
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
Intervention Acceptability: Treatment Evaluation Inventory
Tijdsspanne: Immediately post-intervention
|
Treatment Evaluation Inventory
|
Immediately post-intervention
|
Study Enrollment Rate
Tijdsspanne: Pre-Randomization
|
Enrollment rate calculated from data obtained from recruitment logs
|
Pre-Randomization
|
Study Attrition Rate
Tijdsspanne: 12 months
|
Study attrition will be calculated from study logs
|
12 months
|
Monthly Intervention Calls Completed by Parent Leaders
Tijdsspanne: 12 months
|
Percentage of monthly intervention calls completed by Parent Leaders will be determined from study logs
|
12 months
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
Change in Rate of Average Blood Glucose
Tijdsspanne: Change from baseline at 12 months
|
Hemoglobin A1C from medical record
|
Change from baseline at 12 months
|
Change in Frequency of Adherence
Tijdsspanne: Change from baseline at 12 months
|
Frequency of blood glucose monitoring obtained from blood glucose meter and the Diabetes Self-Management Questionnaire
|
Change from baseline at 12 months
|
Change in Level of Child Diabetes Quality of Life: Pediatric Quality of Life Diabetes Module
Tijdsspanne: Change from baseline at 12 months
|
Pediatric Quality of Life Total Cumulative Scale (scores range from 0-132 with higher scores indicating worse quality of life)
|
Change from baseline at 12 months
|
Change in Level of Parent involvement in diabetes management tasks
Tijdsspanne: Change from baseline at 12 months
|
The Diabetes Family Responsibility Questionnaire (scores range from 17-51 with lower scores indicating parent in primarily responsible for diabetes management)
|
Change from baseline at 12 months
|
Change in Level of Parent self-efficacy
Tijdsspanne: Change from baseline at 12 months
|
Parental Self-Efficacy for Diabetes Management questionnaire scores range from 8-40 with higher scores indicating higher self-efficacy)
|
Change from baseline at 12 months
|
Change in Level of Parent diabetes emotional burden
Tijdsspanne: Change from baseline at 12 months
|
Problem Areas in Diabetes Revised for Parents (scores range from 0-72 with higher scores indicating less emotional burden)
|
Change from baseline at 12 months
|
Change in Level of Parent Depressive Symptoms
Tijdsspanne: Change from baseline at 12 months
|
The Center for Epidemiological Depression Studies-Depression scale (scores range from 12-48 with higher scores indicating more depressive symptoms)
|
Change from baseline at 12 months
|
Change in Level of Parent Social Support
Tijdsspanne: Change from baseline at 12 months
|
2-way Social Support Scale total score (scores range from 0-100 with higher scores indicating more giving and receiving of social support)
|
Change from baseline at 12 months
|
Change in Degree of Impact of diabetes on the family system
Tijdsspanne: Change from baseline at 12 months
|
Diabetes Family Impact Scale (scores range from 0-56 with higher scores indicating greater impact of diabetes on the family)
|
Change from baseline at 12 months
|
Medewerkers en onderzoekers
Sponsor
Onderzoekers
- Hoofdonderzoeker: Ashley M Butler, PhD, Baylor College of Medicine
Publicaties en nuttige links
Nuttige links
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- H-40380
- DP3DK113236 (Subsidie/contract van de Amerikaanse NIH)
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .
Klinische onderzoeken op Diabetes type 1
-
University of Colorado, DenverMassachusetts General Hospital; Beta Bionics, Inc.VoltooidDiabetes mellitus, type 1 | Diabetes type 1 | Diabetestype1 | Diabetes mellitus type 1 | Auto-immuun diabetes | Diabetes Mellitus, insulineafhankelijk | Jeugddiabetes | Diabetes, auto-immuunziekte | Insulineafhankelijke diabetes mellitus 1 | Diabetes Mellitus, insulineafhankelijk, 1 | Diabetes Mellitus,... en andere voorwaardenVerenigde Staten
-
Capillary Biomedical, Inc.VoltooidDiabetes mellitus, type 1 | Diabetes type 1 | Diabetes mellitus type 1 | Diabetes Mellitus, insulineafhankelijk, 1Australië
-
Poznan University of Medical SciencesOnbekendDiabetes mellitus type 1 | Remissie van diabetes type 1 | Chronische complicaties van diabetesPolen
-
University of California, San FranciscoJuvenile Diabetes Research FoundationVoltooidDiabetes mellitus type 1 | Diabetes mellitus, type I | Insulineafhankelijke diabetes mellitus 1 | Diabetes Mellitus, insulineafhankelijk, 1 | IDDMVerenigde Staten, Australië
-
Capillary Biomedical, Inc.BeëindigdDiabetes type 1 | Diabetes mellitus type 1 | Diabetes mellitus, type I | Diabetes Mellitus, insulineafhankelijk, 1 | IDDMOostenrijk
-
National Institute of Allergy and Infectious Diseases...PPD; Rho Federal Systems Division, Inc.; Immune Tolerance Network (ITN)VoltooidDiabetes mellitus type 1 | T1DM | T1D | Nieuwe diabetes mellitus type 1Verenigde Staten, Australië
-
Eledon PharmaceuticalsIngetrokkenBroze type 1 diabetes mellitusVerenigde Staten
-
Shanghai Changzheng HospitalWervingBroze type 1 diabetes mellitusChina
-
University Hospital Inselspital, BerneVoltooidDiabetes complicaties | Diabetes mellitus type 1Zwitserland
-
Spiden AGDCB Research AGVoltooidDiabetes mellitus type 1 | Diabetes mellitus type 1 met hypoglykemie | Diabetes mellitus type 1 met hyperglykemieZwitserland
Klinische onderzoeken op Family Teamwork-Peer Delivery
-
Joslin Diabetes CenterNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Jaeb...Voltooid